KellyElizabethMcCannMDPhD

Oncology • Santa Monica, CA

Breast Cancer, Cancer Genetics/Cancer Risk Assessment

Assistant Clinical Professor

Join to view full profile

Dr. McCann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McCann's full profile

Already have an account?

Office
2336 Santa Monica Blvd., Suite 304
Santa Monica, CA 90404
Phone+1 310-998-4747

Fax+1 310-998-4747

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2011 - 2014
Stanford University School of MedicineClass of 2011, MD, PhD

Certifications & Licensure

OR State Medical License 2013 - Present
CA State Medical License 2014 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

5 citations
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer.
Kelly E McCann, Shari B Goldfarb, Tiffany A Traina, Meredith M Regan, Neelima Vidula
NPJ Breast Cancer. 2024-01-19
5 citations
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
Zev A Wainberg, Arun S Singh, Gottfried E Konecny, Kelly E McCann, J Randolph Hecht
Clinical Cancer Research. 2023-01-04
1 citations
Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observati...
Maitri Kalra, Elizabeth Henry, Kelly McCann, Meghan S Karuturi, Jean G Bustamante Alvarez
JMIR Cancer. 2022-05-19

Press Mentions

TerSera® Presents New Real-World Evidence on Treatment Outcomes of Goserelin (ZOLADEX®) in Women with Breast Cancer at the 2024 San Antonio Breast Cancer SymposiumDecember 12th, 2024
Why More Women Are Living with Stage 4 Breast CancerOctober 28th, 2023
Clinical Challenges: Managing Toxicities of Newer Breast Cancer TherapiesNovember 19th, 2023